Functional differences between two classes of oncogenic mutation in the PIK3CA gene

被引:45
|
作者
Chaussade, Claire [1 ,3 ]
Cho, Kitty [1 ]
Mawson, Claire [2 ]
Rewcastle, Gordon W. [2 ,3 ]
Shepherd, Peter R. [1 ,3 ]
机构
[1] Univ Auckland, Dept Mol Med, Auckland, New Zealand
[2] Univ Auckland, Auckland Canc Soc Res Ctr, Auckland, New Zealand
[3] Univ Auckland, Maurice Wilkins Ctr Mol Biodiscovery, Auckland, New Zealand
关键词
PI; 3-kinase; Cancer; PI-103; PIK-75; Ras; p110; alpha; PHOSPHOINOSITIDE; 3-KINASE; KINASE-ACTIVITY; BIOLOGICAL EVALUATION; HUMAN CANCER; P110-ALPHA; RAS; ISOFORMS; ACTIVATION; MECHANISM; SUBUNIT;
D O I
10.1016/j.bbrc.2009.02.081
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
PIK3CA codes for the p110 alpha isoform of class-IA PI 3-kinase and oncogenic mutations in the helical domain and kinase domain are common in several cancers. We Studied the biochemical properties of a common helical domain mutant (E545K) and a common kinase domain mutant (H1047R). Both retain the ability to autophosphorylate Ser608 of p85 alpha and are also inhibited by a range of PI 3-kinase inhibitors (Wortmanin, LY294002, PI-103 and PIK-75) to a similar extent as WT p110 alpha. Both mutants display an increased V-max but while a PDGF derived diphosphotyrosylpeptide caused all increase in V-max for WT p85 alpha/p110 alpha it did not for the E545K variant and actually decreased V-max for the H1047R variant. Further, the E545K mutant was activated by H-Ras whereas the H1047R mutant was not. Together these results suggest helical domain mutants are in a state mimicking activation by growth factors whereas kinase domain mutants mimic the state activated by H-Ras. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:577 / 581
页数:5
相关论文
共 50 条
  • [1] Oncogenic PIK3CA Mutation and Dysregulation in Human Salivary Duct Carcinoma
    Qiu, Wanglong
    Tong, Guo-Xia
    Turk, Andrew T.
    Close, Lanny G.
    Caruana, SalvatoreM.
    Su, Gloria H.
    BIOMED RESEARCH INTERNATIONAL, 2014, 2014
  • [2] Mutation of the PIK3CA gene in anaplastic thyroid cancer
    García-Rostán, G
    Costa, AM
    Pereira-Castro, I
    Salvatore, G
    Hernandez, R
    Hermsem, MJA
    Herrero, A
    Fusco, A
    Cameselle-Teijeiro, J
    Santoro, M
    CANCER RESEARCH, 2005, 65 (22) : 10199 - 10207
  • [3] Mutation of the PIK3CA gene in ovarian and breast cancer
    Campbell, IG
    Russell, SE
    Choong, DYH
    Montgomery, KG
    Ciavarella, ML
    Hooi, CSF
    Cristiano, BE
    Pearson, RB
    Phillips, WA
    CANCER RESEARCH, 2004, 64 (21) : 7678 - 7681
  • [4] Oncogenic mutations of PIK3CA in human cancers
    Samuels, Y
    Velculescu, VE
    CELL CYCLE, 2004, 3 (10) : 1221 - 1224
  • [5] Oncogenic Mutations of PIK3CA in Human Cancers
    Samuels, Yardena
    Waldman, Todd
    PHOSPHOINOSITIDE 3-KINASE IN HEALTH AND DISEASE, VOL 2, 2011, 347 : 21 - 41
  • [6] Gene of the month: PIK3CA
    Lai, K.
    Killingsworth, M. C.
    Lee, C. S.
    JOURNAL OF CLINICAL PATHOLOGY, 2015, 68 (04) : 253 - 257
  • [7] Two patients with isolated segmental overgrowth candidates for PIK3CA gene mutation testing
    Curtisova, V.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 916 - 916
  • [8] Frequent mutation of the PIK3CA gene in ovarian and breast cancers
    Levine, DA
    Bogomolniy, F
    Yee, CJ
    Lash, A
    Barakat, RR
    Borgen, PI
    Boyd, J
    CLINICAL CANCER RESEARCH, 2005, 11 (08) : 2875 - 2878
  • [9] PIK3CA Mutation Detection by Pyrosequencing
    Baker, C.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2010, 12 (06): : 902 - 902
  • [10] Rare mutation of PIK3CA in meningiomas
    Jesse Chung-sean Pang
    Nellie Yuk Fei Chung
    Norman Hok Ling Chan
    Wai Sang Poon
    Teresa Thomas
    Ho-keung Ng
    Acta Neuropathologica, 2006, 111 : 284 - 285